VAXCYTE, INC. Foreign Currency Transaction Gain Loss Unrealized After Tax
VAXCYTE, INC. (PCVX) reported Foreign Currency Transaction Gain Loss Unrealized After Tax of -$7.37 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossUnrealizedAfterTax · last filed 2026-08-05
- VAXCYTE, INC. foreign currency transaction gain loss unrealized after tax for the quarter ending 2026-06-30 was -$5.17M, a 120.12% decline year-over-year.
- VAXCYTE, INC. foreign currency transaction gain loss unrealized after tax for the quarter ending 2026-03-31 was -$2.20M, a 133.26% decline year-over-year.
- VAXCYTE, INC. foreign currency transaction gain loss unrealized after tax for the quarter ending 2025-12-31 was $1.66M.
- VAXCYTE, INC. foreign currency transaction gain loss unrealized after tax for the quarter ending 2025-09-30 was $789.00K, a 87.77% decline year-over-year.
- VAXCYTE, INC. foreign currency transaction gain loss unrealized after tax for fiscal 2025 was $34.77M.
- VAXCYTE, INC. foreign currency transaction gain loss unrealized after tax for fiscal 2024 was -$4.23M.
- VAXCYTE, INC. foreign currency transaction gain loss unrealized after tax for fiscal 2023 was $0.00.
- VAXCYTE, INC. foreign currency transaction gain loss unrealized after tax for fiscal 2022 was $0.00.
| Period end | Foreign Currency Transaction Gain Loss Unrealized After Tax 3 month | Foreign Currency Transaction Gain Loss Unrealized After Tax 6 month | Foreign Currency Transaction Gain Loss Unrealized After Tax 9 month | Foreign Currency Transaction Gain Loss Unrealized After Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$7.37M 10-Q · filed 2026-08-05 | -$5.72M derived: sum of 3 quarters · filed 2026-08-05 | -$4.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$2.20M 10-Q · filed 2026-05-06 | -$546.00K derived: sum of 2 quarters · filed 2026-05-06 | $243.00K derived: sum of 3 quarters · filed 2026-05-06 | $25.95M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.44M derived: sum of 2 quarters · filed 2026-02-24 | $28.15M derived: sum of 3 quarters · filed 2026-08-05 | $34.77M 10-K · filed 2026-02-24 |
| 2025-09-30 | $789.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $26.50M derived: sum of 2 quarters · filed 2026-08-05 | $33.11M 10-Q · filed 2025-11-04 | $22.43M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $25.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $32.32M 10-Q · filed 2026-08-05 | $21.64M derived: sum of 3 quarters · filed 2026-08-05 | $28.09M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $6.62M 10-Q · filed 2026-05-06 | -$4.07M derived: sum of 2 quarters · filed 2026-05-06 | $2.38M derived: sum of 3 quarters · filed 2026-05-06 | $2.38M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$10.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$4.23M derived: sum of 2 quarters · filed 2026-02-24 | -$4.23M derived: sum of 3 quarters · filed 2026-02-24 | -$4.23M 10-K · filed 2026-02-24 |
| 2024-09-30 | $6.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $6.45M derived: sum of 2 quarters · filed 2025-11-04 | $6.45M 10-Q · filed 2025-11-04 | $6.45M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 10-K · filed 2026-02-24 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-05 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |